TY  - JOUR
AU  - Grigorov, Ilijana
AU  - Pejić, Snežana
AU  - Todorović, Ana
AU  - Drakulić, Dunja
AU  - Veljković, Filip
AU  - Miletić-Vukajlović, Jadranka
AU  - Bobić, Katarina
AU  - Soldatović, Ivan
AU  - Đurašević, Siniša
AU  - Jasnić, Nebojša
AU  - Stanković, Sanja
AU  - Glumac, Sofija
AU  - Mihailović-Vučinić, Violeta
AU  - Milenković, Branislava
PY  - 2023
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/6126
AB  - The careful monitoring of patients with mild/moderate COVID-19 is of particular importance because of the rapid progression of complications associated with COVID-19. For prognostic reasons and for the economic management of health care resources, additional biomarkers need to be identified, and their monitoring can conceivably be performed in the early stages of the disease. In this retrospective cross-sectional study, we found that serum concentrations of high-mobility group box 1 (HMGB1) and heme oxygenase-1 (HO-1), at the time of hospital admission, could be useful biomarkers for COVID-19 management. The study included 160 randomly selected recovered patients with mild to moderate COVID-19 on admission. Compared with healthy controls, serum HMGB1 and HO-1 levels increased by 487.6 pg/mL versus 43.1 pg/mL and 1497.7 pg/mL versus 756.1 pg/mL, respectively. Serum HO-1 correlated significantly with serum HMGB1, oxidative stress parameters (malondialdehyde (MDA), the phosphatidylcholine/lysophosphatidylcholine ratio (PC/LPC), the ratio of reduced and oxidative glutathione (GSH/GSSG)), and anti-inflammatory acute phase proteins (ferritin, haptoglobin). Increased heme catabolism/hemolysis were not detected. We hypothesize that the increase in HO-1 in the early phase of COVID-19 disease is likely to have a survival benefit by providing protection against oxidative stress and inflammation, whereas the level of HMGB1 increase reflects the activity of the innate immune system and represents levels within which the disease can be kept under control.
PB  - Basel: MDPI
T2  - International Journal of Molecular Sciences
T1  - Serum High-Mobility Group Box 1 and Heme Oxygenase 1 as Biomarkers in COVID-19 Patients at Hospital Admission
IS  - 17
VL  - 24
DO  - 10.3390/ijms241713164
SP  - 13164
ER  - 

@article{
author = "Grigorov, Ilijana and Pejić, Snežana and Todorović, Ana and Drakulić, Dunja and Veljković, Filip and Miletić-Vukajlović, Jadranka and Bobić, Katarina and Soldatović, Ivan and Đurašević, Siniša and Jasnić, Nebojša and Stanković, Sanja and Glumac, Sofija and Mihailović-Vučinić, Violeta and Milenković, Branislava",
year = "2023",
abstract = "The careful monitoring of patients with mild/moderate COVID-19 is of particular importance because of the rapid progression of complications associated with COVID-19. For prognostic reasons and for the economic management of health care resources, additional biomarkers need to be identified, and their monitoring can conceivably be performed in the early stages of the disease. In this retrospective cross-sectional study, we found that serum concentrations of high-mobility group box 1 (HMGB1) and heme oxygenase-1 (HO-1), at the time of hospital admission, could be useful biomarkers for COVID-19 management. The study included 160 randomly selected recovered patients with mild to moderate COVID-19 on admission. Compared with healthy controls, serum HMGB1 and HO-1 levels increased by 487.6 pg/mL versus 43.1 pg/mL and 1497.7 pg/mL versus 756.1 pg/mL, respectively. Serum HO-1 correlated significantly with serum HMGB1, oxidative stress parameters (malondialdehyde (MDA), the phosphatidylcholine/lysophosphatidylcholine ratio (PC/LPC), the ratio of reduced and oxidative glutathione (GSH/GSSG)), and anti-inflammatory acute phase proteins (ferritin, haptoglobin). Increased heme catabolism/hemolysis were not detected. We hypothesize that the increase in HO-1 in the early phase of COVID-19 disease is likely to have a survival benefit by providing protection against oxidative stress and inflammation, whereas the level of HMGB1 increase reflects the activity of the innate immune system and represents levels within which the disease can be kept under control.",
publisher = "Basel: MDPI",
journal = "International Journal of Molecular Sciences",
title = "Serum High-Mobility Group Box 1 and Heme Oxygenase 1 as Biomarkers in COVID-19 Patients at Hospital Admission",
number = "17",
volume = "24",
doi = "10.3390/ijms241713164",
pages = "13164"
}

Grigorov, I., Pejić, S., Todorović, A., Drakulić, D., Veljković, F., Miletić-Vukajlović, J., Bobić, K., Soldatović, I., Đurašević, S., Jasnić, N., Stanković, S., Glumac, S., Mihailović-Vučinić, V.,& Milenković, B.. (2023). Serum High-Mobility Group Box 1 and Heme Oxygenase 1 as Biomarkers in COVID-19 Patients at Hospital Admission. in International Journal of Molecular Sciences
Basel: MDPI., 24(17), 13164.
https://doi.org/10.3390/ijms241713164

Grigorov I, Pejić S, Todorović A, Drakulić D, Veljković F, Miletić-Vukajlović J, Bobić K, Soldatović I, Đurašević S, Jasnić N, Stanković S, Glumac S, Mihailović-Vučinić V, Milenković B. Serum High-Mobility Group Box 1 and Heme Oxygenase 1 as Biomarkers in COVID-19 Patients at Hospital Admission. in International Journal of Molecular Sciences. 2023;24(17):13164.
doi:10.3390/ijms241713164 .

Grigorov, Ilijana, Pejić, Snežana, Todorović, Ana, Drakulić, Dunja, Veljković, Filip, Miletić-Vukajlović, Jadranka, Bobić, Katarina, Soldatović, Ivan, Đurašević, Siniša, Jasnić, Nebojša, Stanković, Sanja, Glumac, Sofija, Mihailović-Vučinić, Violeta, Milenković, Branislava, "Serum High-Mobility Group Box 1 and Heme Oxygenase 1 as Biomarkers in COVID-19 Patients at Hospital Admission" in International Journal of Molecular Sciences, 24, no. 17 (2023):13164,
https://doi.org/10.3390/ijms241713164 . .

TY  - JOUR
AU  - Savić, Bojana
AU  - Brkljačić, Jelena
AU  - Glumac, Sofija
AU  - Šarenac, Olivera
AU  - Murphy, David
AU  - Blagojević, Duško
AU  - Japundžić-Žigon, Nina
AU  - Oreščanin-Dušić, Zorana
PY  - 2023
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/5759
AB  - Hypertension and its complications are a leading cause of death in the human
population. Several factors can contribute to development of hypertension, such
as genetic predisposition, high salt intake and environmental stressors, underlying
oxidative stress as one of its key trademarks. We studied the effects of increased salt
intake and chronic stress on blood pressure parameters and the activity and protein
levels of antioxidant enzymes in the heart and aorta of borderline hypertensive rats
(BHRs) with genetic susceptibility to hypertension. All animals were randomized into
four groups: (1) Wistar rats kept in baseline conditions; (2) BHRs kept in baseline
conditions; (3) BHRs drinking 0.9% saline solution; and (4) BHRs drinking 0.9% saline
solution and exposed to repeated heterotypic stress. The BHRs exhibited significantly
higher blood pressure, mitochondrial superoxide dismutase (SOD2) and catalase (CAT)
protein levels and lower glutathione peroxidase (GPx) and glutathione reductase (GR)
activities in the aorta, followed by lower CAT and GPx protein levels and higher CAT
and GR activities in the heart, compared with normotensive Wistar rats. In the BHR
aorta, high salt intake elevated CAT and GPx activities, and when combined with stress
it increased GPx and GR activities. In BHR hearts, high salt intake provoked lower CAT
activity. Adding repeated stress to salt treatment further decreased CAT activity, in
addition to Cu2+–Zn2+ superoxide dismutase (SOD1) and GR activities. The protein
level of CAT was lower, whereas SOD2 and GPx increased. Overall, our results suggest
that BHR hearts are better adapted to oxidative pressure, compared with the aorta,
when exposed to salt and stress.
PB  - Hoboken: Wiley
T2  - Experimental Physiology
T1  - Effects of salt and stress on blood pressure parameters and antioxidant enzyme function in the heart and aorta of borderline hypertensive rats
IS  - 7
VL  - 108
DO  - 10.1113/EP090714
SP  - 946
EP  - 960
ER  - 

@article{
author = "Savić, Bojana and Brkljačić, Jelena and Glumac, Sofija and Šarenac, Olivera and Murphy, David and Blagojević, Duško and Japundžić-Žigon, Nina and Oreščanin-Dušić, Zorana",
year = "2023",
abstract = "Hypertension and its complications are a leading cause of death in the human
population. Several factors can contribute to development of hypertension, such
as genetic predisposition, high salt intake and environmental stressors, underlying
oxidative stress as one of its key trademarks. We studied the effects of increased salt
intake and chronic stress on blood pressure parameters and the activity and protein
levels of antioxidant enzymes in the heart and aorta of borderline hypertensive rats
(BHRs) with genetic susceptibility to hypertension. All animals were randomized into
four groups: (1) Wistar rats kept in baseline conditions; (2) BHRs kept in baseline
conditions; (3) BHRs drinking 0.9% saline solution; and (4) BHRs drinking 0.9% saline
solution and exposed to repeated heterotypic stress. The BHRs exhibited significantly
higher blood pressure, mitochondrial superoxide dismutase (SOD2) and catalase (CAT)
protein levels and lower glutathione peroxidase (GPx) and glutathione reductase (GR)
activities in the aorta, followed by lower CAT and GPx protein levels and higher CAT
and GR activities in the heart, compared with normotensive Wistar rats. In the BHR
aorta, high salt intake elevated CAT and GPx activities, and when combined with stress
it increased GPx and GR activities. In BHR hearts, high salt intake provoked lower CAT
activity. Adding repeated stress to salt treatment further decreased CAT activity, in
addition to Cu2+–Zn2+ superoxide dismutase (SOD1) and GR activities. The protein
level of CAT was lower, whereas SOD2 and GPx increased. Overall, our results suggest
that BHR hearts are better adapted to oxidative pressure, compared with the aorta,
when exposed to salt and stress.",
publisher = "Hoboken: Wiley",
journal = "Experimental Physiology",
title = "Effects of salt and stress on blood pressure parameters and antioxidant enzyme function in the heart and aorta of borderline hypertensive rats",
number = "7",
volume = "108",
doi = "10.1113/EP090714",
pages = "946-960"
}

Savić, B., Brkljačić, J., Glumac, S., Šarenac, O., Murphy, D., Blagojević, D., Japundžić-Žigon, N.,& Oreščanin-Dušić, Z.. (2023). Effects of salt and stress on blood pressure parameters and antioxidant enzyme function in the heart and aorta of borderline hypertensive rats. in Experimental Physiology
Hoboken: Wiley., 108(7), 946-960.
https://doi.org/10.1113/EP090714

Savić B, Brkljačić J, Glumac S, Šarenac O, Murphy D, Blagojević D, Japundžić-Žigon N, Oreščanin-Dušić Z. Effects of salt and stress on blood pressure parameters and antioxidant enzyme function in the heart and aorta of borderline hypertensive rats. in Experimental Physiology. 2023;108(7):946-960.
doi:10.1113/EP090714 .

Savić, Bojana, Brkljačić, Jelena, Glumac, Sofija, Šarenac, Olivera, Murphy, David, Blagojević, Duško, Japundžić-Žigon, Nina, Oreščanin-Dušić, Zorana, "Effects of salt and stress on blood pressure parameters and antioxidant enzyme function in the heart and aorta of borderline hypertensive rats" in Experimental Physiology, 108, no. 7 (2023):946-960,
https://doi.org/10.1113/EP090714 . .

TY  - CONF
AU  - Jovanović Stojanov, Sofija
AU  - Podolski-Renić, Ana
AU  - Dinić, Jelena
AU  - Dragoj, Miodrag
AU  - Jovanović, Mirna
AU  - Stepanović, Ana
AU  - Lupšić, Ema
AU  - Bajović, Radovan
AU  - Glumac, Sofija
AU  - Marić, Dragana
AU  - Ercegovac, Maja
AU  - Pešić, Milica
PY  - 2023
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/5712
AB  - Background: Osimertinib belongs to the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for metastatic EGFR-mutant non-small-cell lung carcinoma (NSCLC) patients. Herein, we studied osimertinib selectivity towards NSCLC cells, its efficacy dependence on the EGFR mutation status, and its ability to evade the classical mechanism of multidrug-resistance (MDR) mirrored in the increased expression of main ATP Binding Cassette (ABC) transporters (ABCB1, ABCC1, and ABCG2).
Methods: Primary patient-derived cultures were established from the NSCLC resections. After short-term culturing (2-3 weeks), a mixed population of cancer and non-cancer cells (around a ratio of 1:1) and two co-cultures of NSCLC cell lines (sensitive NCI-H460 and MDR NCI-H460/R) with lung fibroblasts MRC-5 were treated with 8 chemotherapeutics (cisplatin, carboplatin, paclitaxel, docetaxel, etoposide, vinorelbine, gemcitabine, and pemetrexed) as well as osimertinib. The maximum concentration reached in human plasma to which the patient is exposed during therapy (Cmax) was set as an upper limit and four lower concentrations were also applied during the study. Immunofluorescence assay enabling discrimination of epithelial cancer cells positive to a cocktail of antibodies against cytokeratin 8/18 vs. negative mesenchymal non-cancer cells was conducted using high-content imager ImageXpress Pico (Molecular Devices) with CellReporterXpress 2.9 software. Within the same immunoassay, MDR markers (ABCB1, ABCC1, and ABCG2) were analyzed by corresponding antibodies.
Results: Osimertinib showed selectivity against NSCLC cells, particularly in the patient-derived cell culture without EGFR mutations. Other chemotherapeutics were not selective towards cancer cells, on contrary, they showed higher cytotoxicity in non-cancer cells. Osimertinib did not change the expression of ABCB1 in cancer cells, but it significantly decreased the expression of ABCC1 and ABCG2 transporters in cancer and non-cancer cells.
Conclusions: Osimertinib can be valuable as a selective anticancer drug and an MDR modulator even in NSCLC without EGFR mutations.
PB  - Elsevier Inc.
C3  - Abstract Book of the ESMO Targeted Anticancer Therapies Congress (TAT); 2023 Mar 6-8; Paris, France
T1  - Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts
IS  - 69p
DO  - 10.1016/j.esmoop.2023.100927
ER  - 

@conference{
author = "Jovanović Stojanov, Sofija and Podolski-Renić, Ana and Dinić, Jelena and Dragoj, Miodrag and Jovanović, Mirna and Stepanović, Ana and Lupšić, Ema and Bajović, Radovan and Glumac, Sofija and Marić, Dragana and Ercegovac, Maja and Pešić, Milica",
year = "2023",
abstract = "Background: Osimertinib belongs to the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for metastatic EGFR-mutant non-small-cell lung carcinoma (NSCLC) patients. Herein, we studied osimertinib selectivity towards NSCLC cells, its efficacy dependence on the EGFR mutation status, and its ability to evade the classical mechanism of multidrug-resistance (MDR) mirrored in the increased expression of main ATP Binding Cassette (ABC) transporters (ABCB1, ABCC1, and ABCG2).
Methods: Primary patient-derived cultures were established from the NSCLC resections. After short-term culturing (2-3 weeks), a mixed population of cancer and non-cancer cells (around a ratio of 1:1) and two co-cultures of NSCLC cell lines (sensitive NCI-H460 and MDR NCI-H460/R) with lung fibroblasts MRC-5 were treated with 8 chemotherapeutics (cisplatin, carboplatin, paclitaxel, docetaxel, etoposide, vinorelbine, gemcitabine, and pemetrexed) as well as osimertinib. The maximum concentration reached in human plasma to which the patient is exposed during therapy (Cmax) was set as an upper limit and four lower concentrations were also applied during the study. Immunofluorescence assay enabling discrimination of epithelial cancer cells positive to a cocktail of antibodies against cytokeratin 8/18 vs. negative mesenchymal non-cancer cells was conducted using high-content imager ImageXpress Pico (Molecular Devices) with CellReporterXpress 2.9 software. Within the same immunoassay, MDR markers (ABCB1, ABCC1, and ABCG2) were analyzed by corresponding antibodies.
Results: Osimertinib showed selectivity against NSCLC cells, particularly in the patient-derived cell culture without EGFR mutations. Other chemotherapeutics were not selective towards cancer cells, on contrary, they showed higher cytotoxicity in non-cancer cells. Osimertinib did not change the expression of ABCB1 in cancer cells, but it significantly decreased the expression of ABCC1 and ABCG2 transporters in cancer and non-cancer cells.
Conclusions: Osimertinib can be valuable as a selective anticancer drug and an MDR modulator even in NSCLC without EGFR mutations.",
publisher = "Elsevier Inc.",
journal = "Abstract Book of the ESMO Targeted Anticancer Therapies Congress (TAT); 2023 Mar 6-8; Paris, France",
title = "Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts",
number = "69p",
doi = "10.1016/j.esmoop.2023.100927"
}

Jovanović Stojanov, S., Podolski-Renić, A., Dinić, J., Dragoj, M., Jovanović, M., Stepanović, A., Lupšić, E., Bajović, R., Glumac, S., Marić, D., Ercegovac, M.,& Pešić, M.. (2023). Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts. in Abstract Book of the ESMO Targeted Anticancer Therapies Congress (TAT); 2023 Mar 6-8; Paris, France
Elsevier Inc..(69p).
https://doi.org/10.1016/j.esmoop.2023.100927

Jovanović Stojanov S, Podolski-Renić A, Dinić J, Dragoj M, Jovanović M, Stepanović A, Lupšić E, Bajović R, Glumac S, Marić D, Ercegovac M, Pešić M. Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts. in Abstract Book of the ESMO Targeted Anticancer Therapies Congress (TAT); 2023 Mar 6-8; Paris, France. 2023;(69p).
doi:10.1016/j.esmoop.2023.100927 .

Jovanović Stojanov, Sofija, Podolski-Renić, Ana, Dinić, Jelena, Dragoj, Miodrag, Jovanović, Mirna, Stepanović, Ana, Lupšić, Ema, Bajović, Radovan, Glumac, Sofija, Marić, Dragana, Ercegovac, Maja, Pešić, Milica, "Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts" in Abstract Book of the ESMO Targeted Anticancer Therapies Congress (TAT); 2023 Mar 6-8; Paris, France, no. 69p (2023),
https://doi.org/10.1016/j.esmoop.2023.100927 . .

TY  - CONF
AU  - Stepanović, Ana
AU  - Dinić, Jelena
AU  - Podolski-Renić, Ana
AU  - Jovanović Stojanov, Sofija
AU  - Dragoj, Miodrag
AU  - Jovanović, Mirna
AU  - Lupšić, Ema
AU  - Milićević, Aleksandar
AU  - Glumac, Sofija
AU  - Marić, Dragana
AU  - Ercegovac, Maja
AU  - Pešić, Milica
PY  - 2023
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/5884
AB  - Introduction: Multidrug resistance (MDR) significantly hampers nonsmall cell lung carcinoma (NSCLC) drugs’ efficacy. To evaluate the contribution of MDR markers to anticancer drugs’ sensitivity, we performed pharmacological screening on patient-derived NSCLC cells ex vivo and assessed the expression of MDR markers in cancer and stromal (non-cancer) cells.
Material and Methods: Primary patient-derived cultures were established from the NSCLC resections. After short-term culturing (2-3 weeks), a mixed population of cancer and non-cancer cells were treated with 8 chemotherapeutics (cisplatin, carboplatin, paclitaxel, docetaxel, etoposide, vinorelbine, gemcitabine, and pemetrexed). The maximum concentration reached in human plasma to which the patient is exposed during therapy (Cmax) was set as an upper limit and four lower concentrations were 
also applied during the study. Immunofluorescence assay enabling discrimination of epithelial cancer cells positive to a cocktail of antibodies against cytokeratin 8/18 vs. negative mesenchymal noncancer cells was conducted using high-content imager ImageXpress Pico (Molecular Devices) with CellReporterXpress 2.9 software. Within the same immunoassay, MDR markers (ABCB1, ABCC1, and ABCG2) were analyzed by corresponding antibodies.
Results and Discussions: Among all tested compounds, only gemcitabine increased the number of positive cancer cells to all MDR markers in all investigated primary cell cultures. Pemetrexed did not
change the number of MDR-positive cancer cells. In a patient sample IIIA stage bearing EGFR mutation
(L858R), the number of positive cancer cells to all MDR markers increased upon treatment with cisplatin, carboplatin, paclitaxel, docetaxel, etoposide, vinorelbine, and gemcitabine. Stromal (non-cancer) cells mainly followed the pattern of MDR observed in cancer cells.
Conclusion: Novel functional immunoassay can provide valuable information about the sensitivity of NSCLC to different drugs and possible treatment outcomes based on the
expression of MDR markers.
PB  - John Wiley and Sons Inc
C3  - EACR 2023 Congress: Innovative Cancer Science; 2023 Jun 12-15; Torino, Italy
T1  - Novel functional immunoassay for identification of multidrug resistance markers in non-small cell lung carcinoma patient-derived cells
DO  - 10.1002/1878-0261.13469
SP  - 461
EP  - 462
ER  - 

@conference{
author = "Stepanović, Ana and Dinić, Jelena and Podolski-Renić, Ana and Jovanović Stojanov, Sofija and Dragoj, Miodrag and Jovanović, Mirna and Lupšić, Ema and Milićević, Aleksandar and Glumac, Sofija and Marić, Dragana and Ercegovac, Maja and Pešić, Milica",
year = "2023",
abstract = "Introduction: Multidrug resistance (MDR) significantly hampers nonsmall cell lung carcinoma (NSCLC) drugs’ efficacy. To evaluate the contribution of MDR markers to anticancer drugs’ sensitivity, we performed pharmacological screening on patient-derived NSCLC cells ex vivo and assessed the expression of MDR markers in cancer and stromal (non-cancer) cells.
Material and Methods: Primary patient-derived cultures were established from the NSCLC resections. After short-term culturing (2-3 weeks), a mixed population of cancer and non-cancer cells were treated with 8 chemotherapeutics (cisplatin, carboplatin, paclitaxel, docetaxel, etoposide, vinorelbine, gemcitabine, and pemetrexed). The maximum concentration reached in human plasma to which the patient is exposed during therapy (Cmax) was set as an upper limit and four lower concentrations were 
also applied during the study. Immunofluorescence assay enabling discrimination of epithelial cancer cells positive to a cocktail of antibodies against cytokeratin 8/18 vs. negative mesenchymal noncancer cells was conducted using high-content imager ImageXpress Pico (Molecular Devices) with CellReporterXpress 2.9 software. Within the same immunoassay, MDR markers (ABCB1, ABCC1, and ABCG2) were analyzed by corresponding antibodies.
Results and Discussions: Among all tested compounds, only gemcitabine increased the number of positive cancer cells to all MDR markers in all investigated primary cell cultures. Pemetrexed did not
change the number of MDR-positive cancer cells. In a patient sample IIIA stage bearing EGFR mutation
(L858R), the number of positive cancer cells to all MDR markers increased upon treatment with cisplatin, carboplatin, paclitaxel, docetaxel, etoposide, vinorelbine, and gemcitabine. Stromal (non-cancer) cells mainly followed the pattern of MDR observed in cancer cells.
Conclusion: Novel functional immunoassay can provide valuable information about the sensitivity of NSCLC to different drugs and possible treatment outcomes based on the
expression of MDR markers.",
publisher = "John Wiley and Sons Inc",
journal = "EACR 2023 Congress: Innovative Cancer Science; 2023 Jun 12-15; Torino, Italy",
title = "Novel functional immunoassay for identification of multidrug resistance markers in non-small cell lung carcinoma patient-derived cells",
doi = "10.1002/1878-0261.13469",
pages = "461-462"
}

Stepanović, A., Dinić, J., Podolski-Renić, A., Jovanović Stojanov, S., Dragoj, M., Jovanović, M., Lupšić, E., Milićević, A., Glumac, S., Marić, D., Ercegovac, M.,& Pešić, M.. (2023). Novel functional immunoassay for identification of multidrug resistance markers in non-small cell lung carcinoma patient-derived cells. in EACR 2023 Congress: Innovative Cancer Science; 2023 Jun 12-15; Torino, Italy
John Wiley and Sons Inc., 461-462.
https://doi.org/10.1002/1878-0261.13469

Stepanović A, Dinić J, Podolski-Renić A, Jovanović Stojanov S, Dragoj M, Jovanović M, Lupšić E, Milićević A, Glumac S, Marić D, Ercegovac M, Pešić M. Novel functional immunoassay for identification of multidrug resistance markers in non-small cell lung carcinoma patient-derived cells. in EACR 2023 Congress: Innovative Cancer Science; 2023 Jun 12-15; Torino, Italy. 2023;:461-462.
doi:10.1002/1878-0261.13469 .

Stepanović, Ana, Dinić, Jelena, Podolski-Renić, Ana, Jovanović Stojanov, Sofija, Dragoj, Miodrag, Jovanović, Mirna, Lupšić, Ema, Milićević, Aleksandar, Glumac, Sofija, Marić, Dragana, Ercegovac, Maja, Pešić, Milica, "Novel functional immunoassay for identification of multidrug resistance markers in non-small cell lung carcinoma patient-derived cells" in EACR 2023 Congress: Innovative Cancer Science; 2023 Jun 12-15; Torino, Italy (2023):461-462,
https://doi.org/10.1002/1878-0261.13469 . .

TY  - CONF
AU  - Lakić, Iva
AU  - Đurašević, Siniša
AU  - Ružičić, Aleksandra
AU  - Tosti, Tomislav
AU  - Đurović, Saša
AU  - Glumac, Sofija
AU  - Pavlović, Slađan
AU  - Borković-Mitić, Slavica
AU  - Grigorov, Ilijana
AU  - Stanković, Sanja
AU  - Pejić, Snežana
AU  - Todorović, Ana
AU  - Drakulić, Dunja
AU  - Jasnić, Nebojša
AU  - Đorđević, Jelena
AU  - Todorović, Zoran
PY  - 2022
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/5933
AB  - Сепса је стање опасно по живот узроковано нерегулисаним и прекомерним
одговором на инфекцију, које праћено инфламацијом и поремећеним
метаболизмом липида доводи до постепеног отказивања органа.1,2 Мелдонијум је
антиинфламаторни лек који се користи за лечење исхемије миокарда.3 Он делује
тако што преусмерава производњу енергије са оксидације масних киселина на
гликолизу, као пут који троши мање кисеоника. На овај начин мелдонијум
негативно утиче на метаболизам липида. Истраживали смо ефекте
четворонедељног претретмана мелдонијумом на ток фекалне сепсе (ФИП) и сепсе
изазиване липополисахаридом (ЛПС), код мужјака пацова. Изненађујуће, у
условима фекалне сепсе, мелдонијум је повећао стопу морталитета животиња у
поређењу са групом која није третирана мелдонијумом. Анализе оксидативног и
инфламаторног статуса ткива (срце, јетра, бубрези) потврдиле су
антиинфламаторне, антиапоптотске и антинекротичке ефекте мелдонијума, код оба
модела сепсе. Када је реч о производњи енергије, упркос неким сличностима,
утврђене су разлике у ова два модела. Једна од очигледних разлика је у одговору
симпатоадреналног система, који је изостао код ФИП модела, док је код ЛПС
модела довео до двоструког повећања концентрације катехоламина у серуму. Ова
студија показује важност ненарушене производње енергије скрећући пажњу на
потребу ревизије постојећих смерница у клиничком лечењу сепсе, али и отвара пут
за откривање нових терапијских приступа.
AB  - Sepsa je stanje opasno po život uzrokovano neregulisanim i prekomernim odgovorom na infekciju, koje praćeno inflamacijom i poremećenim metabolizmom lipida dovodi do postepenog otkazivanja organa.1,2 Meldonijum je antiinflamatorni lek koji se koristi za lečenje ishemije miokarda.3 On deluje tako što preusmerava proizvodnju energije sa oksidacije masnih kiselina na glikolizu, kao put koji troši manje kiseonika. Na ovaj način meldonijum negativno utiče na metabolizam lipida. Istraživali smo efekte četvoronedeljnog pretretmana meldonijumom na tok fekalne sepse (FIP) i sepse izazivane lipopolisaharidom (LPS), kod mužjaka pacova. Iznenađujuće, u uslovima fekalne sepse, meldonijum je povećao stopu mortaliteta životinja u poređenju sa grupom koja nije tretirana meldonijumom. Analize oksidativnog i inflamatornog statusa tkiva (srce, jetra, bubrezi) potvrdile su antiinflamatorne, antiapoptotske i antinekrotičke efekte meldonijuma, kod oba modela sepse. Kada je reč o proizvodnji energije, uprkos nekim sličnostima, utvrđene su razlike u ova dva modela. Jedna od očiglednih razlika je u odgovoru simpatoadrenalnog sistema, koji je izostao kod FIP modela, dok je kod LPS modela doveo do dvostrukog povećanja koncentracije kateholamina u serumu. Ova studija pokazuje važnost nenarušene proizvodnje energije skrećući pažnju na potrebu revizije postojećih smernica u kliničkom lečenju sepse, ali i otvara put za otkrivanje novih terapijskih pristupa.
PB  - Belgrade: Serbian Biological Society
C3  - Knjiga sažetaka: Treći Kongres biologa Srbije: Osnovna i primenjena istraživanja: Metodika nastave; 2022 Sep 21-25; Zlatibor, Serbia
T1  - Efekti pretretmana meldonijumom na tokove različitih modela sepsi kod pacova
T1  - Ефекти претретмана мелдонијумом на токове различитих модела сепси код пацова
SP  - 340
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_5933
ER  - 

@conference{
author = "Lakić, Iva and Đurašević, Siniša and Ružičić, Aleksandra and Tosti, Tomislav and Đurović, Saša and Glumac, Sofija and Pavlović, Slađan and Borković-Mitić, Slavica and Grigorov, Ilijana and Stanković, Sanja and Pejić, Snežana and Todorović, Ana and Drakulić, Dunja and Jasnić, Nebojša and Đorđević, Jelena and Todorović, Zoran",
year = "2022",
abstract = "Сепса је стање опасно по живот узроковано нерегулисаним и прекомерним
одговором на инфекцију, које праћено инфламацијом и поремећеним
метаболизмом липида доводи до постепеног отказивања органа.1,2 Мелдонијум је
антиинфламаторни лек који се користи за лечење исхемије миокарда.3 Он делује
тако што преусмерава производњу енергије са оксидације масних киселина на
гликолизу, као пут који троши мање кисеоника. На овај начин мелдонијум
негативно утиче на метаболизам липида. Истраживали смо ефекте
четворонедељног претретмана мелдонијумом на ток фекалне сепсе (ФИП) и сепсе
изазиване липополисахаридом (ЛПС), код мужјака пацова. Изненађујуће, у
условима фекалне сепсе, мелдонијум је повећао стопу морталитета животиња у
поређењу са групом која није третирана мелдонијумом. Анализе оксидативног и
инфламаторног статуса ткива (срце, јетра, бубрези) потврдиле су
антиинфламаторне, антиапоптотске и антинекротичке ефекте мелдонијума, код оба
модела сепсе. Када је реч о производњи енергије, упркос неким сличностима,
утврђене су разлике у ова два модела. Једна од очигледних разлика је у одговору
симпатоадреналног система, који је изостао код ФИП модела, док је код ЛПС
модела довео до двоструког повећања концентрације катехоламина у серуму. Ова
студија показује важност ненарушене производње енергије скрећући пажњу на
потребу ревизије постојећих смерница у клиничком лечењу сепсе, али и отвара пут
за откривање нових терапијских приступа., Sepsa je stanje opasno po život uzrokovano neregulisanim i prekomernim odgovorom na infekciju, koje praćeno inflamacijom i poremećenim metabolizmom lipida dovodi do postepenog otkazivanja organa.1,2 Meldonijum je antiinflamatorni lek koji se koristi za lečenje ishemije miokarda.3 On deluje tako što preusmerava proizvodnju energije sa oksidacije masnih kiselina na glikolizu, kao put koji troši manje kiseonika. Na ovaj način meldonijum negativno utiče na metabolizam lipida. Istraživali smo efekte četvoronedeljnog pretretmana meldonijumom na tok fekalne sepse (FIP) i sepse izazivane lipopolisaharidom (LPS), kod mužjaka pacova. Iznenađujuće, u uslovima fekalne sepse, meldonijum je povećao stopu mortaliteta životinja u poređenju sa grupom koja nije tretirana meldonijumom. Analize oksidativnog i inflamatornog statusa tkiva (srce, jetra, bubrezi) potvrdile su antiinflamatorne, antiapoptotske i antinekrotičke efekte meldonijuma, kod oba modela sepse. Kada je reč o proizvodnji energije, uprkos nekim sličnostima, utvrđene su razlike u ova dva modela. Jedna od očiglednih razlika je u odgovoru simpatoadrenalnog sistema, koji je izostao kod FIP modela, dok je kod LPS modela doveo do dvostrukog povećanja koncentracije kateholamina u serumu. Ova studija pokazuje važnost nenarušene proizvodnje energije skrećući pažnju na potrebu revizije postojećih smernica u kliničkom lečenju sepse, ali i otvara put za otkrivanje novih terapijskih pristupa.",
publisher = "Belgrade: Serbian Biological Society",
journal = "Knjiga sažetaka: Treći Kongres biologa Srbije: Osnovna i primenjena istraživanja: Metodika nastave; 2022 Sep 21-25; Zlatibor, Serbia",
title = "Efekti pretretmana meldonijumom na tokove različitih modela sepsi kod pacova, Ефекти претретмана мелдонијумом на токове различитих модела сепси код пацова",
pages = "340",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_5933"
}

Lakić, I., Đurašević, S., Ružičić, A., Tosti, T., Đurović, S., Glumac, S., Pavlović, S., Borković-Mitić, S., Grigorov, I., Stanković, S., Pejić, S., Todorović, A., Drakulić, D., Jasnić, N., Đorđević, J.,& Todorović, Z.. (2022). Efekti pretretmana meldonijumom na tokove različitih modela sepsi kod pacova. in Knjiga sažetaka: Treći Kongres biologa Srbije: Osnovna i primenjena istraživanja: Metodika nastave; 2022 Sep 21-25; Zlatibor, Serbia
Belgrade: Serbian Biological Society., 340.
https://hdl.handle.net/21.15107/rcub_ibiss_5933

Lakić I, Đurašević S, Ružičić A, Tosti T, Đurović S, Glumac S, Pavlović S, Borković-Mitić S, Grigorov I, Stanković S, Pejić S, Todorović A, Drakulić D, Jasnić N, Đorđević J, Todorović Z. Efekti pretretmana meldonijumom na tokove različitih modela sepsi kod pacova. in Knjiga sažetaka: Treći Kongres biologa Srbije: Osnovna i primenjena istraživanja: Metodika nastave; 2022 Sep 21-25; Zlatibor, Serbia. 2022;:340.
https://hdl.handle.net/21.15107/rcub_ibiss_5933 .

Lakić, Iva, Đurašević, Siniša, Ružičić, Aleksandra, Tosti, Tomislav, Đurović, Saša, Glumac, Sofija, Pavlović, Slađan, Borković-Mitić, Slavica, Grigorov, Ilijana, Stanković, Sanja, Pejić, Snežana, Todorović, Ana, Drakulić, Dunja, Jasnić, Nebojša, Đorđević, Jelena, Todorović, Zoran, "Efekti pretretmana meldonijumom na tokove različitih modela sepsi kod pacova" in Knjiga sažetaka: Treći Kongres biologa Srbije: Osnovna i primenjena istraživanja: Metodika nastave; 2022 Sep 21-25; Zlatibor, Serbia (2022):340,
https://hdl.handle.net/21.15107/rcub_ibiss_5933 .

TY  - JOUR
AU  - Đurašević, Siniša
AU  - Ružičić, Aleksandra
AU  - Lakić, Iva
AU  - Tosti, Tomislav
AU  - Đurović, Saša
AU  - Glumac, Sofija
AU  - Pavlović, Slađan
AU  - Borković Mitić, Slavica
AU  - Grigorov, Ilijana
AU  - Stanković, Sanja
AU  - Jasnić, Nebojša
AU  - Đorđević, Jelena
AU  - Todorović, Zoran
PY  - 2021
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4413
AB  - Sepsis is a life-threatening condition caused by the dysregulated and overwhelming
response to infection, accompanied by an exaggerated pro-inflammatory state and lipid metabolism
disturbance leading to sequential organ failure. Meldonium is an anti-ischemic and anti-inflammatory
agent which negatively interferes with lipid metabolism by shifting energy production from fatty
acid oxidation to glycolysis, as a less oxygen-demanding pathway. Thus, we investigated the effects
of a four-week meldonium pre-treatment on faecal-induced sepsis in Sprague-Dawley male rats.
Surprisingly, under septic conditions, meldonium increased animal mortality rate compared with
the meldonium non-treated group. However, analysis of the tissue oxidative status did not provide
support for the detrimental effects of meldonium, nor did the analysis of the tissue inflammatory
status showing anti-inflammatory, anti-apoptotic, and anti-necrotic effects of meldonium. After
performing tissue lipidomic analysis, we concluded that the potential cause of the meldonium
harmful effect is to be found in the overall decreased lipid metabolism. The present study underlines
the importance of uninterrupted energy production in sepsis, closely drawing attention to the possible
harmful effects of lipid-mobilization impairment caused by certain therapeutics. This could lead to
the much-needed revision of the existing guidelines in the clinical treatment of sepsis while paving
the way for discovering new therapeutic approaches.
PB  - Basel: MDPI
T2  - International Journal of Molecular Sciences
T1  - The effects of a meldonium pre-treatment on the course of the faecal-induced sepsis in rats
IS  - 18
VL  - 22
DO  - 10.3390/ijms22189698
SP  - 9698
ER  - 

@article{
author = "Đurašević, Siniša and Ružičić, Aleksandra and Lakić, Iva and Tosti, Tomislav and Đurović, Saša and Glumac, Sofija and Pavlović, Slađan and Borković Mitić, Slavica and Grigorov, Ilijana and Stanković, Sanja and Jasnić, Nebojša and Đorđević, Jelena and Todorović, Zoran",
year = "2021",
abstract = "Sepsis is a life-threatening condition caused by the dysregulated and overwhelming
response to infection, accompanied by an exaggerated pro-inflammatory state and lipid metabolism
disturbance leading to sequential organ failure. Meldonium is an anti-ischemic and anti-inflammatory
agent which negatively interferes with lipid metabolism by shifting energy production from fatty
acid oxidation to glycolysis, as a less oxygen-demanding pathway. Thus, we investigated the effects
of a four-week meldonium pre-treatment on faecal-induced sepsis in Sprague-Dawley male rats.
Surprisingly, under septic conditions, meldonium increased animal mortality rate compared with
the meldonium non-treated group. However, analysis of the tissue oxidative status did not provide
support for the detrimental effects of meldonium, nor did the analysis of the tissue inflammatory
status showing anti-inflammatory, anti-apoptotic, and anti-necrotic effects of meldonium. After
performing tissue lipidomic analysis, we concluded that the potential cause of the meldonium
harmful effect is to be found in the overall decreased lipid metabolism. The present study underlines
the importance of uninterrupted energy production in sepsis, closely drawing attention to the possible
harmful effects of lipid-mobilization impairment caused by certain therapeutics. This could lead to
the much-needed revision of the existing guidelines in the clinical treatment of sepsis while paving
the way for discovering new therapeutic approaches.",
publisher = "Basel: MDPI",
journal = "International Journal of Molecular Sciences",
title = "The effects of a meldonium pre-treatment on the course of the faecal-induced sepsis in rats",
number = "18",
volume = "22",
doi = "10.3390/ijms22189698",
pages = "9698"
}

Đurašević, S., Ružičić, A., Lakić, I., Tosti, T., Đurović, S., Glumac, S., Pavlović, S., Borković Mitić, S., Grigorov, I., Stanković, S., Jasnić, N., Đorđević, J.,& Todorović, Z.. (2021). The effects of a meldonium pre-treatment on the course of the faecal-induced sepsis in rats. in International Journal of Molecular Sciences
Basel: MDPI., 22(18), 9698.
https://doi.org/10.3390/ijms22189698

Đurašević S, Ružičić A, Lakić I, Tosti T, Đurović S, Glumac S, Pavlović S, Borković Mitić S, Grigorov I, Stanković S, Jasnić N, Đorđević J, Todorović Z. The effects of a meldonium pre-treatment on the course of the faecal-induced sepsis in rats. in International Journal of Molecular Sciences. 2021;22(18):9698.
doi:10.3390/ijms22189698 .

Đurašević, Siniša, Ružičić, Aleksandra, Lakić, Iva, Tosti, Tomislav, Đurović, Saša, Glumac, Sofija, Pavlović, Slađan, Borković Mitić, Slavica, Grigorov, Ilijana, Stanković, Sanja, Jasnić, Nebojša, Đorđević, Jelena, Todorović, Zoran, "The effects of a meldonium pre-treatment on the course of the faecal-induced sepsis in rats" in International Journal of Molecular Sciences, 22, no. 18 (2021):9698,
https://doi.org/10.3390/ijms22189698 . .

TY  - CONF
AU  - Lakić, Iva
AU  - Đurašević, Siniša
AU  - Ružičić, Aleksandra
AU  - Tosti, Tomislav
AU  - Đurović, Saša
AU  - Glumac, Sofija
AU  - Pavlović, Slađan
AU  - Borković Mitić, Slavica
AU  - Grigorov, Ilijana
AU  - Stanković, Sanja
AU  - Jasnić, Nebojša
AU  - Todorović, Zoran
AU  - Đorđević, Jelena
PY  - 2021
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/4896
AB  - Background: Sepsis is a life-threatening condition caused by the dysregulated and overwhelming response to infection, accompanied by exaggerated pro-inflammatory state and lipid metabolism disturbance leading to sequential organ failure.1, 2 Meldonium is an anti-ischemic and anti-inflammatory agent, clinically used to treat myocardial ischemia.3 By shifting energy production from fatty acid oxidation to glycolysis, as an oxygen less consuming pathway, meldonium interferes negatively with lipid metabolism. 
Methods: Thus, we investigated the effects of a 4-week meldonium pre-treatment in 300 mg/kg b.m./day dosage on the course of the sepsis induced by a single intraperitoneal injection of faeces (0.5 g faeces/1 mL saline/100 g b.m.)in Sprague-Dawley male rats. The degree of the heart injury was evaluated by measuring tissue pro-apoptotic Bax and anti-apoptotic Bcl-2 ratio, tissue level of the necrotic marker - high mobility group box 1 protein level (HMGB1), together with the heart histology analysis. Sepsis-associated heart inflammation
was assessed by measuring level of an activated form of NF-kB p65 (phospho-NF-κB p65).
Results: In the heart whole homogenates of the septic group of animals (S) HMGB1 level increased 1.7-fold, in comparison to control rats, while meldonium reduced sepsis-induced increase by 18 % (M+S). The underlying mechanism of the proinflammatory action of HMGB1 includes activation of NF-κB signalling
pathways tissue, so the increased HMGB1 level was followed by a 1.4-fold increase of p-NF-κB p65 in the heart of the S group of rats and a 19 % decreased in the heart of M+S group. The apoptotic marker Bax/Bcl-2 ratio changed in the same manner: 1.4-fold increase in the heart of animals from the S group and a 32 % decrease in the heart of the M+S group. On the other hand, heart histology analysis shows that meldonium worsened the heart histological score, causing the severe and diffuse interstitial mononuclear infiltration along with a greater loss of myocytes and myofibrillar contraction band necrosis. The heart lipidomic analysis suggests that meldonium exhibits potentially harmful effects under septic condition due to the lipid-mobilization impairment.
Conclusion: Meldonium exerted anti-inflammatory, anti-apoptotic, and anti- necrotic effects, while it worsened the septic rat heart histology.
PB  - Banja Luka: Association of Medical Doctors
PB  - Banja Luka: Faculty of Medicine, University of Banja Luka
C3  - 7th Meeting of the European section and 8th Meeting of the North American section of the International academy of cardiovascular sciences (IACS); 2021 Sep 20-23; Banja Luka, Bosnia and Herzegovina
T1  - The Effects of a Meldonium Pre-Treatment on the Sepsis-Induced Rat Heart Injury
SP  - 57
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_4896
ER  - 

@conference{
author = "Lakić, Iva and Đurašević, Siniša and Ružičić, Aleksandra and Tosti, Tomislav and Đurović, Saša and Glumac, Sofija and Pavlović, Slađan and Borković Mitić, Slavica and Grigorov, Ilijana and Stanković, Sanja and Jasnić, Nebojša and Todorović, Zoran and Đorđević, Jelena",
year = "2021",
abstract = "Background: Sepsis is a life-threatening condition caused by the dysregulated and overwhelming response to infection, accompanied by exaggerated pro-inflammatory state and lipid metabolism disturbance leading to sequential organ failure.1, 2 Meldonium is an anti-ischemic and anti-inflammatory agent, clinically used to treat myocardial ischemia.3 By shifting energy production from fatty acid oxidation to glycolysis, as an oxygen less consuming pathway, meldonium interferes negatively with lipid metabolism. 
Methods: Thus, we investigated the effects of a 4-week meldonium pre-treatment in 300 mg/kg b.m./day dosage on the course of the sepsis induced by a single intraperitoneal injection of faeces (0.5 g faeces/1 mL saline/100 g b.m.)in Sprague-Dawley male rats. The degree of the heart injury was evaluated by measuring tissue pro-apoptotic Bax and anti-apoptotic Bcl-2 ratio, tissue level of the necrotic marker - high mobility group box 1 protein level (HMGB1), together with the heart histology analysis. Sepsis-associated heart inflammation
was assessed by measuring level of an activated form of NF-kB p65 (phospho-NF-κB p65).
Results: In the heart whole homogenates of the septic group of animals (S) HMGB1 level increased 1.7-fold, in comparison to control rats, while meldonium reduced sepsis-induced increase by 18 % (M+S). The underlying mechanism of the proinflammatory action of HMGB1 includes activation of NF-κB signalling
pathways tissue, so the increased HMGB1 level was followed by a 1.4-fold increase of p-NF-κB p65 in the heart of the S group of rats and a 19 % decreased in the heart of M+S group. The apoptotic marker Bax/Bcl-2 ratio changed in the same manner: 1.4-fold increase in the heart of animals from the S group and a 32 % decrease in the heart of the M+S group. On the other hand, heart histology analysis shows that meldonium worsened the heart histological score, causing the severe and diffuse interstitial mononuclear infiltration along with a greater loss of myocytes and myofibrillar contraction band necrosis. The heart lipidomic analysis suggests that meldonium exhibits potentially harmful effects under septic condition due to the lipid-mobilization impairment.
Conclusion: Meldonium exerted anti-inflammatory, anti-apoptotic, and anti- necrotic effects, while it worsened the septic rat heart histology.",
publisher = "Banja Luka: Association of Medical Doctors, Banja Luka: Faculty of Medicine, University of Banja Luka",
journal = "7th Meeting of the European section and 8th Meeting of the North American section of the International academy of cardiovascular sciences (IACS); 2021 Sep 20-23; Banja Luka, Bosnia and Herzegovina",
title = "The Effects of a Meldonium Pre-Treatment on the Sepsis-Induced Rat Heart Injury",
pages = "57",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_4896"
}

Lakić, I., Đurašević, S., Ružičić, A., Tosti, T., Đurović, S., Glumac, S., Pavlović, S., Borković Mitić, S., Grigorov, I., Stanković, S., Jasnić, N., Todorović, Z.,& Đorđević, J.. (2021). The Effects of a Meldonium Pre-Treatment on the Sepsis-Induced Rat Heart Injury. in 7th Meeting of the European section and 8th Meeting of the North American section of the International academy of cardiovascular sciences (IACS); 2021 Sep 20-23; Banja Luka, Bosnia and Herzegovina
Banja Luka: Association of Medical Doctors., 57.
https://hdl.handle.net/21.15107/rcub_ibiss_4896

Lakić I, Đurašević S, Ružičić A, Tosti T, Đurović S, Glumac S, Pavlović S, Borković Mitić S, Grigorov I, Stanković S, Jasnić N, Todorović Z, Đorđević J. The Effects of a Meldonium Pre-Treatment on the Sepsis-Induced Rat Heart Injury. in 7th Meeting of the European section and 8th Meeting of the North American section of the International academy of cardiovascular sciences (IACS); 2021 Sep 20-23; Banja Luka, Bosnia and Herzegovina. 2021;:57.
https://hdl.handle.net/21.15107/rcub_ibiss_4896 .

Lakić, Iva, Đurašević, Siniša, Ružičić, Aleksandra, Tosti, Tomislav, Đurović, Saša, Glumac, Sofija, Pavlović, Slađan, Borković Mitić, Slavica, Grigorov, Ilijana, Stanković, Sanja, Jasnić, Nebojša, Todorović, Zoran, Đorđević, Jelena, "The Effects of a Meldonium Pre-Treatment on the Sepsis-Induced Rat Heart Injury" in 7th Meeting of the European section and 8th Meeting of the North American section of the International academy of cardiovascular sciences (IACS); 2021 Sep 20-23; Banja Luka, Bosnia and Herzegovina (2021):57,
https://hdl.handle.net/21.15107/rcub_ibiss_4896 .